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strains  of  serotype  G1,  G2, G3,  G4  and G9  has  been  developed  by the  Serum  Institute  of  India  Ltd, in
collaboration  with  the National  Institute  of Allergy  and  Infectious  Diseases  (NIAID),  USA.  The  vaccine
underwent  animal  toxicity  studies  and  Phase  I and  II studies  in adults,  toddlers  and  infants.  It  has  been
found  safe  and  immunogenic  and  will  undergo  a large  Phase  III  study  to assess  efﬁcacy  against  severe
rotavirus  gastroenteritis.
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. Introduction
Black et al. estimated annual global mortality in 2008 due to
iarrheal diseases in children 0–5 years of age was around 1.5
illion, based on single-cause disease models and analysis of
ital registration data, about 500,000 of which were attributed to
otavirus infection. The world’s poorest countries of Asia and sub-
aharan Africa bear the maximum burden of these deaths [1]. Based
n a systematic review and meta-analysis of studies which assessed
otavirus diarrhea, Tate et al. calculated 453,000 global deaths in
008 (95% CI 420,000–494,000) in children younger than ﬁve years;
2% of them (98,621 deaths) in India alone [2]. It is also estimated
hat rotavirus causes 457,000–884,000 hospitalizations and over
wo million outpatient visits every year in India [3].
Although rotavirus vaccines are commercially available, they are
naffordable in developing countries. Notwithstanding the recent
ecommendation by the World Health Organization (WHO) for the
nclusion of rotavirus vaccination in the national immunization
chedules of all countries, the vaccine’s supply continues to be an
ssue for the countries with greatest need [4]. The need is urgent
ecause children in low-income countries are infected earlier in life
nd with limited access to health care, their illness is likely to be
evere, even leading to death [5].Widespread use of rotavirus vaccines is estimated to be able to
vert 2.4 million deaths by 2025, with annual reductions of up to
25,000 child deaths [6]. However, realizing the vaccine’s potential
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must be supported by an adequate supply of high-quality WHO-
prequaliﬁed vaccines by manufacturers in developing countries
without relying on multi-national corporations.
The epidemiology of rotavirus is a complex, dynamic phe-
nomenon. Globally, ﬁve genotypes (G1–G4, and G9) account for 88%
of all strains [7]. Researchers have extensively studied the molec-
ular epidemiology of rotaviruses in India [8]. The most common
G (VP7) serotypes found were G1 and G2, however, studies have
observed a high prevalence of G9 strains of up to 15% in various
Indian cities. In a recent study conducted by SII in collaboration
with the National Institute of Cholera and Enteric Diseases (NICED)
in a rural area of West Bengal, India, G9 P[4] (27%), G1 [P8] (18%)
and G2 P[4] (14%) were the predominant genotypes in the study
population [9].
Rotavirus candidate vaccine development has followed two
views regarding the importance of serotype-speciﬁc protection.
Many candidates are based on the theory that protection is not
solely dependent on neutralizing antibody. These candidates con-
tain single rotavirus strains and include the Rotarix vaccine. On
the other hand, several candidate vaccines are based on the con-
cept that neutralizing antibody is the primary determinant of
protection. These candidates, including RotaTeq, are composed
of multiple rotavirus strains representative of the major human
rotavirus serotypes [10]. The SIIL candidate vaccine belongs to the
latter group and includes ﬁve most prevalent serotypes [7].
1.1. Bovine reassortant vaccinesThe most extensively evaluated approach for live attenu-
ated oral vaccines is based on the “Jennerian” concept, involving
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ttenuated for humans [11]. In view of the inconsistency of pro-
ection from animal rotavirus-based vaccines, efforts began to
evelop reassortant rotavirus strains that contained some genes
rom the animal rotavirus parent and some genes from the human
otavirus parent, termed the “modiﬁed Jennerian” approach [12].
P7 was thought to be important for protection; therefore, human-
nimal reassortant rotaviruses for use as vaccines included human
P7 genes to provide protective immune responses. A pentava-
ent human-bovine (WC3) reassortant live-attenuated, oral vaccine
RotaTeq) developed by Merck Research Co. is currently licensed
13].
Another multivalent bovine-human reassortant vaccine was
ndependently developed by the National Institute of Allergy and
nfectious Diseases (NIAID). This bovine rotavirus tetravalent (BRV-
V) vaccine incorporates four reassortant viruses with a VP7 gene
f either a G1, G2, G3, or G4 human serotype and 10 genes from the
ovine rotavirus UK strain. NIAID conducted phase1 studies of the
ndividual vaccine components, as well as phase 1 and 2 studies
f a quadrivalent version of the vaccine in the US and in Finland
14–16].
The initial studies in adults, children and infants with this
etravalent G1–G4 BRV formulation (BRV-TV) in the US, demon-
trated that each of the components was able to infect the
olunteers as determined by vaccine shedding in the stools and the
nduction of immune responses [14]. The vaccine was safe; and had
o impact on the immune responses of routine childhood immu-
izations. Vesikari et al. in Finland compared the same tetravalent
accine to the rhesus tetravalent vaccine (RRV-TV, later licensed
s RotaShield) [15]. Both vaccines were equally efﬁcacious, how-
ver, the BRV-TV was less reactogenic than the RRV-TV, which was
ssociated with febrile reactions and diminished appetite. In the
tudy, the vaccine induced immune responses in 97% of the infants
ested and showed 90% efﬁcacy against severe rotavirus gastroen-
eritis (SRVGE) during two rotavirus seasons (CI: 35–99%), though
he size of this study was limited. These ﬁndings clearly support
he immunogenicity, safety and potential for efﬁcacy of BRV-PV.
.2. Vaccine development at Serum Institute of India Ltd.
With the emergence of the G9 and G8 serotypes, the NIAID
dded human-bovine (UK) reassortants with G8 and G9 speciﬁcities
o the tetravalent vaccine, thereby formulating a hexavalent vac-
ine for use in developing countries [17]. The UK bovine rotavirus
6[P5] strain was used to construct single gene substitution
eassortants in which the G gene derives from human rotavirus
erotypes G1, G2, G3, G4, G8 and G9, and all the other genes derived
rom the UK bovine strain.
Non-exclusive licenses for the production of the human-bovine
UK) vaccine were granted to the Chengdu Institute of Biologi-
al Products (CDIBP) (China), Instituto Butantan (Brazil), Shantha
iotech (India) and Serum Institute of India Ltd. (SIIL) (India). SIIL
igned the agreement with NIAID in 2005.
SIIL is one of the largest vaccine manufacturers in the world.
eadquartered at Pune, India, it has been manufacturing vac-
ines since 1971. Since 1992, SIIL has supplied vaccines to UNICEF
nd Pan-American Health Organization (PAHO) after receiving the
andatory WHO  prequaliﬁcation for the quality of its vaccines.
urrently, 19 of its vaccines are WHO  prequaliﬁed and supplied
o immunization programs of many developing countries. It is esti-
ated that SIIL is the largest supplier of DTwP-HB-Hib vaccine and
easles vaccine in the world.
After transfer of these reassortants from NIAID, SIIL startedorking on them in 2007. The vaccine was formulated as a
yophilized product which was resuspended in antacid buffer
ust before use to address the issue of potential inactivation
f rotaviruses in the stomach. The antacid buffer diluent was (2014) A124–A128 A125
formulated using 9.6 g/l of citric acid and 25.6 g/l of sodium bicar-
bonate together with water for injection.
The viruses are grown in Vero cells which are kidney epithelial
cells of African green monkey (Cercopithecus aethiops) and were
procured from American Type Culture Collection (ATCC), USA. The
Vero cell bank was  prepared at SIIL and characterized to qualify
for the vaccine production. Cell growth kinetics and virus growth
kinetics were studied and the formulation with the lyophilization
cycle was  developed at SIIL. The pre-clinical toxicity and clinical lots
were manufactured in a dedicated facility at SIIL in compliance with
current good manufacturing practices (cGMP). These lots showed
excellent lot-to-lot consistency and stability. The vaccine is stable
for three years at 2–8 ◦C, and 25 ◦C, for two years at 37 ◦C and for
six months at 40 ◦C.
The SII BRV-PV was  initially formulated as a combination of the
six reassortants at equivalent titers. These reassortants represent
the most common G serotypes. The G9 component is of particular
interest to India as it has circulated in Indian infants for over two
decades.
The live attenuated vaccine has a three dose regimen since it is
known that, natural rotavirus infection confers protection against
subsequent infection and that this protection increases with each
new infection and reduces the severity of the diarrhea [18]. Rotateq,
another bovine reassortant vaccine is already licensed for a three
dose schedule.
1.3. Preclinical toxicology studies
SII conducted single- and repeated-dose toxicity studies of
rotavirus vaccine in rodents (Wistar rats) and non-rodents (New
Zealand white rabbits) by oral gavage administrations in an accred-
ited laboratory in India under strict good laboratory practices (GLP).
These studies were conducted with a hexavalent vaccine which
included G1, G2, G3, G4, G8 and G9 reassortants. Single dose stud-
ies included 60 rats and 18 rabbits in three groups while repeated
dose studies included 70 rats in four groups and 18 rabbits in three
groups. The vaccine formulation had virus titers in the range of
106.62 FFU to 107.79 FFU.
A dose of 2.5 ml  of reconstituted vaccine, placebo or normal
saline were administered on day one to animal groups. In repeated
dose studies, additional doses were administered on day 15, 29
and 43. All the animals were observed for mortality, clinical signs,
weight changes and food intake. We collected stool samples 72 h
after each administration. Necropsy was carried out on day 8 and 57
during the single dose and repeat dose toxicity studies, respectively.
The vaccine in single- and repeated-dose toxicity studies in
Wistar rats had no effects on their general health. There were no
changes in body temperature, cumulative net body weight gains
and hematological, clinical chemistry and urinalysis parameters in
animals of either sex. Fecal samples were negative for the pres-
ence of rotavirus antigen in all the animals. No gross or microscopic
histopathological changes were detected.
The vaccine administered as single and repeated dose by the oral
route in New Zealand white rabbits also showed no effects on gen-
eral health. There were no toxic signs and mortality; no effects on
body temperature, body weight, cumulative net body weight gains
and food intake. There were no changes on the hematological, clin-
ical chemistry and urinalysis parameters tested in animals of either
sex. Fecal samples were negative for the presence of rotavirus anti-
gen in all the animals. No gross or microscopic histopathological
changes were detected in either sex.All the animals were positive for rotavirus antibodies before
administration of the vaccine and remained positive 43 days after
vaccination. The IgA was  determined by using enzyme-linked
immunosorbent assay (ELISA) as described previously [19].
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Table 1
Reactogenicity of 105.2 FFU/serotype BRV-PV vaccine in infants.
Solicited symptom BRV-PV Placebo
Participants assessed 27 30
At least one solicited symptom, n (%) 14 (51.85%) 21 (70.00%)
Diarrhea, n (%) 1 (3.70%) 2 (6.67%)
Vomiting, n (%) 11 (40.74%) 13 (43.33%)
Fever, n (%) 3 (11.11%) 8 (26.67%)
Decreased appetite, n (%) 5 (18.52%) 5 (16.67%)
Decreased activity, n (%) 4 (14.81%) 1 (3.33%)
Irritability, n (%) 9 (33.33%) 12 (40.00%)












































Reactogenicity of 105.6 FFU/serotype BRV-PV vaccine in infants.
Solicited symptom BRV-PV Placebo
Participants assessed 30 30
At least one solicited symptoms, n (%) 18 (60.00%) 20 (66.67%)
Diarrhea, n (%) 3 (10.00%) 2 (6.67%)
Vomiting, n (%) 8 (26.67%) 7 (23.33%)
Fever, n (%) 3 (10.00%) 5 (16.67%)
Decreased appetite, n (%) 6 (20.00%) 4 (13.33%)
Decreased activity, n (%) 3 (10.00%) 2 (6.67%)
2. Planned Phase III studiesAntipyretic use, n (%) 4 (14.81%) 7 (23.33%)
Thus, SII hexavalent BRV vaccine did not cause any toxicity when
dministered as single and repeated dose by the oral route in Wis-
ar rats and New Zealand white rabbits. The studies also proved that
long with the antigens, the formulation which contains stabiliz-
rs and antacid is safe. These results opened prospects for human
linical studies on the vaccine.
.4. Clinical studies
Considering rotavirus serotype distribution in India, a pen-
avalent formulation which comprised of G1, G2, G3, G4 and G9
erotypes was used for clinical development (Fig. 1). Three clinical
tudies (Phase I, Phase IIa and Phase IIb) have been conducted on SII
RV-PV in India (Registration numbers CTRI/2009/091/000821 and
TRI/2010/091/003064). The study populations included adults,
oddlers and infants.
All studies were approved by the Drug Controller General of
ndia (DCGI) and institutional ethics committees. They complied
ith all the national regulatory and ethical standards as well as
he ICH good clinical practices (GCP). An independent Data Safety
onitoring Board (DSMB) monitored the safety and rights of the
tudy subjects. The sera samples for rotavirus speciﬁc IgA antibod-
es were tested using IgA ELISA at the Christian Medical College,
ellore (India) [19] and stool samples for shedding were tested
sing rotavirus antigen detection kit (Generic Assays, Germany)
t Metropolis Laboratory, Pune. Seroconversion was  deﬁned as a
hange in IgA concentration from <20 U/ml to ≥20 U/ml, or ≥3 fold
ise in IgA titers in case of baseline titers ≥20 U/ml.
The Phase I study was a randomized, double-blind, placebo con-
rolled study to assess the safety of a single oral dose of SII BRV-PV
equentially in healthy adults, toddlers and infants. The study also
ssessed the immunogenicity and shedding of the vaccine. A single
ral dose of the vaccine containing 106 FFU/serotype was  investi-
ated in 54 subjects (18 adults, 18 toddlers and 18 infants) who
eceived vaccine or placebo in 2:1 ratio.
BRV-PV was found safe and well tolerated in all three age groups.
here was no serious adverse event (SAE). The few adverse events
eported were mild and transient. Vaccine related events included
ausea, loss of appetite, diarrhea and vomiting (Table 1). Except
or a few minor changes, the hematology, biochemistry and urine
nalysis results remained normal in all the groups.
No shedding was seen in stool samples. As expected, the single
ose of the vaccine did not show immune response in adults and
oddlers. However, infants showed a small immune response (28%)
hich was encouraging.
This was followed by a randomized, double-blind, placebo con-
rolled Phase IIa study which assessed the formulation of 105.2
FU/serotype in 60 healthy infants. SII BRV-PV/placebo was admin-
stered in 1:1 ratio as three doses with at least four weeks interval
etween doses. The study assessed the safety, immunogenicity and
hedding of the vaccine.Irritability, n (%) 9 (30.00%) 6 (20.00%)
Respiratory symptoms 11 (36.67%) 9 (30.00%)
Antipyretic use, n (%) 9 (30.00%) 5 (16.67%)
Close post-vaccination follow-up showed the vaccine to be safe
and well tolerated. A summary of the solicited vaccine reactogenic-
ity is summarized in Table 2. Almost all the events were mild
and transient. Two  SAEs (urinary tract infections and septicemia)
unrelated to study vaccines were reported and both recovered
uneventfully. We  saw no effect on laboratory parameters.
Three doses of the vaccine were found immunogenic. The sero-
conversion post dose 2 was  36% and 7.14%, in vaccine and placebo
arms respectively (p = 0.0160). The corresponding post dose 3 sero-
conversion were 48% and 21.43% (p = 0.0492) (Table 3). The post
dose 3 GMTs in vaccine and placebo arms were 18.55 U/ml; and
7.31 U/ml.
Following these satisfactory results, a randomized, double-
blind, placebo controlled Phase IIb study was conducted which
assessed the formulation of 105.6 FFU/serotype in 60 healthy
infants. SII BRV-PV/placebo was administered in 1:1 ratio as three
doses with at least four weeks interval.
This formulation of the vaccine was also found safe and well
tolerated. A summary of the solicited vaccine reactogenicity is
summarized in Table 2. Almost all the events were mild and tran-
sient. No SAE was  reported and there was no effect on laboratory
parameters.
Three doses of the 105.6 FFU/serotype formulation induced a sig-
niﬁcant immune response (Table 3). The seroconversion post dose
2 was  56.67% and 11.54%, in vaccine and placebo arms respectively
(p value <0.05). The corresponding post dose 3 ﬁgures were 60%
and 7.69% (p < 0.05).
The seroconversion rates indicated that the 105.6 FFU/serotype
formulation is immunogenic in infants. These results are similar
to those reported for the Rotarix (GSK) in an Indian study where
the seroconversion rates were 58.3% [95% CI: 48.7; 67.4] in the
Rotarix group and 6.3%; [95% CI: 2.5; 12.5] in the placebo group
[20]. Another Indian study on the 116E vaccine showed 89.7% sero-
conversion in the vaccine arm and 28.1% in the placebo arm [21].
Another Indian study on Rotateq showed 83% 3-fold rise (serocon-
version) in serum IgA antibodies; however the study had no placebo
arm [22].
In developed countries, the seroresponses to rotavirus vaccines
are high. The examples include a Korean study on Rotarix (88.1%)
[23], a Korean study on Rotateq (94.7%) [24], a Japanese study on
Rotarix (85.3%) [25], an European study on Rotarix (85.5–89.2%)
[26], and a Finnish study on Rotarix (83.7–90.5%) [27].
However, for reasons not completely understood, the serore-
sponses are lower in developing countries. The examples include
an African study on Rotateq (73.8–82.5%) [28], a Brazil study on
Rotarix (54.7–74.4%) [29] and a Latin American study on Rotarix
(61–65%) [30]. Our results on the 105.6 FFU/serotype formulations
are in line with these studies.A large Phase III clinical trial on the 105.6 FFU/serotype for-
mulation is now planned to achieve licensure in India as well as
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Fig. 1. Human and bovine reassortant pentavalent vaccine with VP7 serotype G1, G2, G3, G4 and G9 speciﬁcity.
Modiﬁed from Ref. [14].
Table 3
Seroconversion with 105.2 FFU/serotype formulation (Phase IIa) and 105.6 FFU/serotype formulation (Phase IIb) of SII BRV-PV.
Study arm Phase IIa Phase IIb
Post dose 2 Post dose 3 Post dose 2 Post dose 3























fPlacebo  2/28 (7.14%) 6/28 (2
p-Valuea 0.0160 0.0492 
a Fisher’s exact test.
requaliﬁcation by WHO  for global application. Given the limited
nowledge on correlates of protection for rotavirus vaccine, this
hase III clinical trial is designed to demonstrate that the vaccine
s efﬁcacious against rotavirus gastroenteritis. In addition, through
lose surveillance, the trial will greatly expand the safety database
vailable for the product.
This double blind randomized placebo controlled study will be
onducted in around 7500 infants at multiple sites in India. BRV-PV
r placebo will be administered in 1:1 ratio at 6, 10 and 14 weeks
f age along with Universal Immunization program (UIP) vaccines.
 close follow up will be maintained for rotavirus gastroenteritis
ases as well as safety issues till two years of age. Immunogenicity
f the vaccine will be assessed in a subset along with polio type 1,
 and 3 antibodies.
Since UIP vaccines will be given concurrently with the three
oses of BRV-PV, a separate Phase III study will formally assess
he potential interference of the vaccine with routine UIP immu-
izations. In that study, the immunogenicity of three consecutively
anufactured lots will also be assessed to establish manufacturing
ot-to-lot consistency.
. Future plansApart from the lyophilized presentation, SIIL is also working on
 fully liquid formulation; ready-to-use vaccine which contains the
eassortants of the same serotypes. Animal toxicity studies of this
ormulation are anticipated to start in 2014. 3/26 (11.54%) 2/26 (7.69%)
0.0006 0.0001
4. Conclusions
After technology transfer from NIAID, SIIL successfully contin-
ued the further development of the BRV-PV. The results of the
pre-clinical and clinical studies of the formulation developed at SIIL
have shown that it is safe and immunogenic. The vaccine is now
poised to enter the pivotal study for licensure. Eventual commer-
cial availability of the vaccine will be important for public health
programs in the developing world.
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